25% to completion
$3,780 / $15,000 goal
"Calcinosis cutis is an incredibly painful, debilitating disorder. Because little is known about its etymology, prevention, and effective treatment, Nancy-Jean Anthony had to endure it without relief for years. We want to fund research to find an effective cure/treatment."
— The Anthony Family

Nancy-Jean Anthony was a vivacious, kindhearted, giving person who suffered immensely from Calcinosis Cutis; her family and friends would like to find a cure for this painful condition.

For many years, Nancy-Jean Anthony endured Calcinosis Cutis (http://www.eblue.org/article/S0190-9622(10)02123-7/abstract), a painful and debilitating condition in which calcium deposits form in the skin. She was not a "victim" of this condition, nor did she "lose her battle" to it; despite the sheer intensity of the pain, she lived her life fiercely and stoically.

Little is known about the cause(s) of Calcinosis Cutis and treatment is ineffective and sometimes counterproductive (e.g., some research has found that surgery/removal promotes more growth). Despite numerous visits to various doctors over the years, Nancy-Jean Anthony had virtually no answers and zero relief. She did have a few surgeries, which turned out to be both painful and ineffective, as the calcium buildups often returned to that location and/or elsewhere.

Nancy-Jean was an ebullient, stoic, and profoundly strong woman. She was also a devoted and loving wife to Robert Anthony. A fiercely loving and protective mother, sister, daughter, and aunt. And a dear friend to many. She was a role model for how to live and how to love. 

We want to prevent others from suffering unnecessarily as she did. We hope that you will honor the wonderful person that she was by helping us in this endeavor.

What your Donation Supports

Your donation will support research being done by Dr. Lorinda Chung's lab at Stanford University. 

There are currently no effective medical therapies for the prevention or treatment of calcinosis. Surgical removal can sometimes be an option for individual lesions, but oftentimes, calcinosis is too diffuse to remove, and can also recur after surgical removal.

Dr. Chung's lab has developed the first ever clinical trial to test a therapy for the prevention of calcinosis progression. The study will evaluate whether Treprostinil is effective in slowing down the progression of calcinosis affecting the hands of patients with scleroderma. In order to better quantify the progression of calcinosis over time, they have developed a novel x-ray scoring system, which they will use in this clinical trial. If this study shows a signal that Treprostinil can slow down the progression of calcinosis, Dr. Chung hopes to perform a large, multi-center study to support a new indication and approval of the first medical therapy for the prevention of calcinosis progression.